![Bristol-Myers Squibb / Cetuximab / Tyrosine kinase receptors / Immune system / Symphogen / Monoclonal antibody therapy / Monoclonal antibodies / HER2/neu / Zalutumumab / Immunology / Biology / Medicine Bristol-Myers Squibb / Cetuximab / Tyrosine kinase receptors / Immune system / Symphogen / Monoclonal antibody therapy / Monoclonal antibodies / HER2/neu / Zalutumumab / Immunology / Biology / Medicine](https://www.pdfsearch.io/img/77c01d1cbc1863bdb9bf93b4be4f2110.jpg)
| Document Date: 2014-01-14 13:28:11 Open Document File Size: 1,82 MBShare Result on Facebook
Company Merck KGaA / Genentech / Novo A/S / PhD / / Country Japan / / Currency EUR / / Event FDA Phase / / IndustryTerm Cancer Treatment / oncology product / drug product / reproducible single batch manufacturing process / / MedicalCondition tumor / truly innovative multi-target antibody mixture products Tumor / Cancer / NSCLC / Angiogenesis Tumor / / MedicalTreatment chemo / / Person Symphogen / Antibody Therapeutics Kirsten Drejer / / Position Chief Executive Officer / / Product Erbitux / Japan / /
SocialTag |